What is HC Wainwright’s Estimate for LXRX Q1 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – HC Wainwright issued their Q1 2026 earnings per share estimates for Lexicon Pharmaceuticals in a report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.12) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 41.94% and a negative net margin of 101.08%.The firm had revenue of $5.49 million during the quarter, compared to analyst estimates of $3.14 million.

A number of other research analysts have also weighed in on the company. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $3.95.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.71 on Monday. The stock’s 50-day simple moving average is $1.36 and its 200 day simple moving average is $1.33. The stock has a market capitalization of $724.49 million, a price-to-earnings ratio of -12.21 and a beta of 0.94. The company has a debt-to-equity ratio of 0.46, a quick ratio of 4.87 and a current ratio of 4.88. Lexicon Pharmaceuticals has a 52-week low of $0.32 and a 52-week high of $1.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Security National Bank of Sioux City Iowa IA bought a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth approximately $31,000. Hudson Bay Capital Management LP bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at approximately $26,000. Leonteq Securities AG purchased a new position in Lexicon Pharmaceuticals in the 4th quarter worth approximately $34,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Lexicon Pharmaceuticals by 400.0% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 26,000 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $39,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Insiders Place Their Bets

In other Lexicon Pharmaceuticals news, Director Invus Global Management, Llc acquired 1,538,462 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were bought at an average price of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the transaction, the director owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Raymond Debbane acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $1.47 per share, with a total value of $147,000.00. Following the purchase, the director directly owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. This trade represents a 5.54% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 1,790,462 shares of company stock worth $2,369,981 in the last quarter. 13.90% of the stock is currently owned by company insiders.

More Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — GAAP EPS of -$0.04 vs. -$0.07 consensus and revenue of $5.49M vs. $3.14M expected, which relieved near-term execution concerns and likely helped the stock. Earnings beat summary
• Positive Sentiment: Clinical progress: management confirmed sotagliflozin pivotal milestones are on schedule (including planned NDA resubmission in T1D and enrollment of the SONATA HCM study) and reported a positive End‑of‑Phase‑2 meeting with the FDA for pilavapadin, supporting Phase 3 readiness. These program updates materially de‑risk future value drivers. Press release with clinical updates
• Positive Sentiment: Balance-sheet boost — management disclosed more than $100M in additional cash from a capital raise plus a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press release with financing detail
• Positive Sentiment: Analyst upgrade / price-target raise — H.C. Wainwright reiterated a Buy rating and raised its target to $6, signaling bullish analyst conviction and providing a large implied upside that can attract momentum buyers. Analyst note / PT raise
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript; these provide more detail for investors but are informational rather than catalytic. Earnings call transcript
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative return on equity; consensus still forecast a full‑year loss (current consensus ~ -$0.66 EPS), so fundamentals remain challenged absent clinical or commercial validation. Earnings / metrics summary
• Negative Sentiment: Biotech execution and regulatory risk persist — upcoming clinical readouts and the NDA resubmission are binary events that could reverse gains if outcomes disappoint. Clinical & regulatory update

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.